Premium
Theranostics Through the Synergistic Cooperation of Heterometallic Complexes
Author(s) -
Redrado Marta,
FernándezMoreira Vanesa,
Gimeno M. Concepción
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000833
Subject(s) - traceability , nanotechnology , chemistry , combinatorial chemistry , cancer therapy , computational biology , biochemical engineering , computer science , cancer , materials science , biology , engineering , genetics , software engineering
Heterometallic drugs are emerging as a great alternative to conventional metallodrugs. Careful selection of different metallic fragments makes possible to enhance not only the therapeutic potential by a synergistic effect, but also to incorpore key features like traceability. Drugs that integrate traceability and therapy in one system are known as theranostic agents. In cancer research, theranostic agents are becoming increasingly important. They deliver crucial information regarding their biological interplay that can ultimately be used for optimization. The well‐established therapeutic potential of Pt II ‐, Ru II ‐ and Au I ‐based drugs combined with the outstanding optical properties of d 6 transition metal complexes grant the delivery of traceable metallodrugs. These species can be easily fine‐tuned through modification of their respective ligands to provide a new generation of drugs.